Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia
Authors
Keywords
-
Journal
BLOOD
Volume 121, Issue 1, Pages 136-147
Publisher
American Society of Hematology
Online
2012-11-20
DOI
10.1182/blood-2012-01-407742
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells
- (2010) E. Hertlein et al. BLOOD
- Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells
- (2010) X. Liang et al. BLOOD
- Targeting microRNAs in cancer: rationale, strategies and challenges
- (2010) Ramiro Garzon et al. NATURE REVIEWS DRUG DISCOVERY
- Targeted Delivery Systems for Oligonucleotide Therapeutics
- (2009) Bo Yu et al. AAPS Journal
- Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation
- (2009) Daniela Rožková et al. INTERNATIONAL JOURNAL OF CANCER
- 5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen
- (2009) Susan O'Brien et al. JOURNAL OF CLINICAL ONCOLOGY
- Selective Recognition of Rituximab-Functionalized Gold Nanoparticles by Lymphoma Cells Studied with 3D Imaging
- (2009) Angelina Weiss et al. Journal of Physical Chemistry C
- Molecular and cellular mechanisms of CLL: novel therapeutic approaches
- (2009) Lisa Pleyer et al. Nature Reviews Clinical Oncology
- Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia
- (2008) M. Vogler et al. BLOOD
- Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells
- (2008) R. Lapalombella et al. BLOOD
- Accessing the therapeutic potential of immunostimulatory nucleic acids
- (2008) Winfried Barchet et al. CURRENT OPINION IN IMMUNOLOGY
- Antisense, RNAi, and gene silencing strategies for therapy: Mission possible or impossible?
- (2008) E RAYBURN et al. DRUG DISCOVERY TODAY
- Antitumor Activity of G3139 Lipid Nanoparticles (LNPs)
- (2008) Xiaogang Pan et al. MOLECULAR PHARMACEUTICS
- Transferrin Receptor-Targeted Lipid Nanoparticles for Delivery of an Antisense Oligodeoxyribonucleotide against Bcl-2
- (2008) Xiaojuan Yang et al. MOLECULAR PHARMACEUTICS
- Sequence- and target-independent angiogenesis suppression by siRNA via TLR3
- (2008) Mark E. Kleinman et al. NATURE
- BCL-2 family antagonists for cancer therapy
- (2008) Guillaume Lessene et al. NATURE REVIEWS DRUG DISCOVERY
- Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides
- (2008) R. Juliano et al. NUCLEIC ACIDS RESEARCH
- The BCL-2 protein family: opposing activities that mediate cell death
- (2007) Richard J. Youle et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started